Skip to main content
SpringerLink
Log in

Cetuximab [Erbitux] will be the gold standard for the treatment of squamous cell carcinoma of the head and neck by 2010,

  • Media release
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

REFERENCE

  1. Decision Resources Inc.Imclone/Bristol-Myers Squibb/Merck Serono's Erbitux will Overtake Cisplatin/5-Fluorouracil as the Clinical Gold Standard for the Treatment of Head and Neck Cancer by 2010. Media Release: 17 Jul 2007. Available from: URL: http://www.decisionresources.com

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cetuximab [Erbitux] will be the gold standard for the treatment of squamous cell carcinoma of the head and neck by 2010,. Pharmacoecon. Outcomes News 533, 10 (2007). https://doi.org/10.1007/BF03296141

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03296141

Keywords

Search

Navigation